You are here

Share:

Search Technologies

Showing 1-20 of 74 results found

Assay for Arf GTP-binding Proteins

The National Cancer Institute's Laboratory of Cellular and Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an antibody-based proteomics assay.

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop antibody-based therapeutic against MERS-CoV, including animal studies, cGMP manufacturing, and clinical trials.

Method and Device for Selectively Labeling RNA

The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.

Biomarker signature development: microRNAs for biodosimetry

Alterations in microRNAs (miRNAs), a type of small non-coding RNAs, have been reported in cells/tumors subjected to radiation exposure, implying that miRNAs play an important role in cellular stress response to radiation. NCI researchers evaluated small non-coding RNAs, long non-coding RNAs (lncRNA), and mRNA, as potential non-invasive biomarkers for radiation biodosimetry. The NCI Radiation Oncology Branch seeks parties interested in licensing or co-development of RNA biomarker signature(s) for radiation biodosimetry.

High-throughput Assay to Identify New Cancer Drugs

The National Cancer Institute, Laboratory of Molecular Pharmacology seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.

Ratio Based Biomarkers for the Prediction of Cancer Survival

The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.

Reporter Plasmid to Identify Cancer Stem Cells

The National Cancer Institute’s Laboratory of Cancer Biology and Genetics seeks partners to co-develop lentiviral plasmids, a research tool for visualizing and purifying cancer stem cells.

Detection of Colorectal Cancer with Two Novel Heme-Related Molecules in Human Feces

Mortality from colorectal cancer (CRC) can be reduced by detecting the cancer or its precursor, colorectal adenoma (CRA), so that it can be removed at an early stage.  Current tests involve screening stool specimens for blood, especially for hemoglobin.  The fecal immunochemical test (FIT) for hemoglobin is positive in stool for only about 60% of early-stage and 85% of advanced CRC cases, with a false-positive rate of less than 10%.  Researchers at the NCI have developed an assay with better accuracy and seek licensing and/or co-development research collaborations for the commercialization of the assay.

Methods of analyzing virus-derived therapeutics

Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.

Diagnostic Assays for the Detection of Thyroid Cancer

The Eunice Kennedy Shriver National Institute of Child and Human Development’s (NICHD) Pediatric Growth and Nutrition Branch seek partners to co-develop a diagnostic assay to detect thyroid cancer.

Gene Signature for Predicting Solid Tumors Patient Prognosis

The National Cancer Institute’s Laboratory of Human Carcinogenesis seeks parties to license or co-develop a method of predicting the prognosis of a patient diagnosed with hepatocellular carcinoma (HCC) or breast cancer by detecting expression of one or more cancer-associated genes, and a method of identifying an agent for use in treating HCC.

Pages